Kalaris Therapeutics, Inc. (KLRS) › Cash & EquivalentsKalaris Therapeutics, Inc. (KLRS) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $61.08M2020: $122.66M2021: $201.66M2022: $106.09M2023: $90.12M2024: $1.64M2025: $98.05M$98.05M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$98.05M+5882.6%2024$1.64M-98.2%2023$90.12M-15.1%2022$106.09M-47.4%2021$201.66M+64.4%2020$122.66M+100.8%2019$61.08M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share